In patients with osteoporosis, sclerostin is a candidate biomarker due to its association with lower bone mineral content and bone density [52]; therefore, a sclerostin inhibitor could be a promising therapy for bone-related disorders. The gene discussed is SOST; the disease is osteoporosis.